Artia Global Partners »

Alpine Immune Sciences shares owned by Artia Global Partners

Quarter-by-quarter ownership of Alpine Immune Sciences (ALPN) shares owned by Artia Global Partners from 13F filings

Historical chart of Artia Global Partners investment in Alpine Immune Sciences

Tip: Access up to 7 years of quarterly data

All positions including Alpine Immune Sciences held by Artia Global Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alpine Immune Sciences by Artia Global Partners

Quarter filed Position value Share count Share price at filing
2024-03-31 $2.0M 52k 39.64

More positions owned by Artia Global Partners

Eli Lilly & Co Put Put Option
Novo-nordisk A S Adr (NVO)
Eli Lilly & Co. (LLY)
Merck & Co (MRK)
Viking Therapeutics (VKTX)
Abbvie (ABBV)
Intra Cellular Therapies (ITCI)
Argenx Se Sponsored Adr (ARGX)
Astrazeneca Sponsored Adr (AZN)
Vertex Pharmaceuticals Incorporated (VRTX)
Axsome Therapeutics (AXSM)
Ocular Therapeutix (OCUL)
Cytokinetics Com New (CYTK)
Neurocrine Biosciences (NBIX)
Disc Medicine (IRON)

View all positions for Artia Global Partners

Top funds holding Alpine Immune Sciences

Decheng Capital
venBio Select Advisor
BlackRock
Frazier Life Sciences Management
T. Rowe Price Associates
State Street Corporation
Vanguard Group
Cormorant Asset Management
OrbiMed Advisors
Lynx1 Capital Management
Paradigm Biocapital Advisors
Darwin Global Management
Commodore Capital
Octagon Capital Advisors
Avidity Partners Management

View all funds holding Alpine Immune Sciences